Effectiveness and Safety of Tofacitinib in Biologic-Naïve Elderly Patients with Ulcerative Colitis

    January 2025 in “ Journal of Crohn s and Colitis
    A Singh D.M., Vandana Midha, A Bhardwaj, Rajesh Sharma, Dharmatma Singh, Rajesh Mahajan, Ajit Sood
    Image of study
    TLDR Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
    This study evaluated the effectiveness and safety of tofacitinib in 35 biologic-naïve elderly patients (≥60 years) with moderate-to-severe ulcerative colitis at a tertiary care center in North India. The primary outcome, steroid-free clinical remission at both weeks 8 and 52, was achieved in 25.71% of patients. At week 8, clinical remission, steroid-free remission, and clinical response were observed in 51.42%, 42.85%, and 62.85% of patients, respectively. By week 52, these rates increased to 62.85% for both clinical remission and steroid-free remission, with a clinical response in 77.14% of patients. Common adverse events included hair loss (17.14%), sadness of mood (11.42%), and dyslipidemia (8.57%). The findings suggest that tofacitinib is a viable treatment option for this patient population.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 7 results

    Similar Research

    5 / 708 results